FC
BBIO icon

FORA Capital’s BridgeBio Pharma BBIO Stock Holding History

FORA Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,035
Closed -$1.4M – 436
2025
Q4 		$1.4M Buy
18,035
+6,919
+62% +$454K 0.17% 148
2025
Q3 		$577K Sell
11,116
-11,558
-51% -$564K 0.1% 255
2025
Q2 		$979K Sell
22,674
-754
-3% -$27.4K 0.11% 223
2025
Q1 		$810K Buy
+23,428
New +$790K 0.08% 266
2024
Q1 		– Sell
-35,415
Closed -$1.43M – 411
2023
Q4 		$1.43M Buy
+35,415
New +$1.06M 0.12% 208
2021
Q3 		– Sell
-2,033
Closed -$124K – 401
2021
Q2 		$124K Sell
2,033
-301
-13% -$17.2K 0.02% 543
2021
Q1 		$144K Sell
2,334
-8,626
-79% -$564K 0.05% 345
2020
Q4 		$779K Buy
10,960
+7,212
+192% +$348K 0.12% 194
2020
Q3 		$141K Buy
3,748
+1,197
+47% +$37.7K 0.09% 232
2020
Q2 		$83K Buy
+2,551
New +$77.7K 0.03% 542

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FORA Capital's BBIO Position: Q1 2026 in Review

FORA Capital sold out of BridgeBio Pharma (BBIO) in Q1 2026, closing a stake of 18,035 shares — an estimated $1.4M sold.

FORA Capital first reported a position in BBIO in Q2 2020 and held it in 10 quarters. The position peaked at $1.43M in Q4 2023. 460 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • FORA Capital reported no remaining BridgeBio Pharma position as of Q1 2026 after selling out during the quarter.
  • FORA Capital sold 18,035 BridgeBio Pharma shares in Q1 2026, an estimated $1.4M.
  • FORA Capital first reported a position in BridgeBio Pharma in Q2 2020 and held it in 10 quarters.
  • FORA Capital's BridgeBio Pharma position peaked at $1.43M in Q4 2023.
  • 460 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on FORA Capital's 13F filing for Q1 2026, filed 15 May 2026.